Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Targovax ASA ( (GB:0RIS) ) has provided an update.
Circio Holding ASA has completed the registration of a NOK 3.6 million directed share issue with the Norwegian Register of Business Enterprises, increasing its share capital to NOK 128,944,012.20 divided into 214,906,687 shares with a nominal value of NOK 0.60 each. The new shares are expected to be issued and delivered today, strengthening the company’s capital base as it advances its circular RNA platform and continues development of its TG01 immuno-oncology program through external collaborations.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Its proprietary circVec platform is designed to deliver more durable and potent gene expression than conventional mRNA-based viral and non-viral systems, targeting applications in genetic medicine, cell therapy and chronic diseases, alongside a legacy immuno-oncology vaccine program for RAS-mutated cancers.
Average Trading Volume: 4,354,944
Current Market Cap: NOK251.7M
Learn more about 0RIS stock on TipRanks’ Stock Analysis page.